Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

log into MY ENETS

ENETS Abstract Search

#2038 Overall Survival, Progression-Free Survival, and Quality of Life Updates from the NETTER-1 Study: 177Lu-Dotatate vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors

Introduction: The NETTER-1 final per-protocol statistical analysis (cut–off date 24.07.2015) of PFS, the primary endpoint of the study, showed a significant difference (p<0.0001) between the treatment arms.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Jonathan S

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,

#1676 NETTER-1 Phase III Trial: Recent Findings on Quality of Life in Patients with Midgut Neuroendocrine Tumors

Introduction: Impairment in quality of life caused by tumor load and hormone-related symptoms is frequent in GEP-NET patients. In the Phase III NETTER-1 trial, patients with advanced, progressive midgut NETs were randomized to treatment with 177Lu-DOTATATE (177Lu; Lutathera®) or high-dose (60 mg) Octreotide LAR (Oct).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: 177Lu-DOTATATE, PRRT, NET, Quality of Life,

#1508 NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy and Safety Results

Introduction: There are limited therapeutic options for patients with advanced midgut NETs progressing on first-line somatostatin analog therapy.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Strosberg J

Authors: Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D,

Keywords: Lutathera, PRRT, NET,

#439 Chromogranin A (CgA) and Pancreastatin (PcSt) as Predictors of Peptide Receptor Radionuclide Therapy (PRRT) Outcomes in Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)

Introduction: CgA and PcSt are widely used in assessing response to treatment in mNETs.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sharma N, Naraev B, Engelman E, Zimmerman M, Bushnell D,

Keywords: pancreastatin, chromogranin, peptide, receptor, radionuclide, therapy, PRRT, neuroendocrine, tumors,

#395 Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) in North American Cohort of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors (mNETs)

Introduction: PRRT is an accepted treatment in Europe for patients (pts) with mNETs, but considered investigational in the USA.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Naraev B, Sharma N, Engelman E, Bushnell D, O'Dorisio T,

Keywords: peptide, receptor, radionuclide, therapy, PRRT, neuroendocrine, tumors,